AstraZeneca to invest $2bn in Summit for ADC combination therapies
AstraZeneca will acquire around 109,000 preferred shares convertible into Summit common stock at a 1:1,000 ratio.
Drug Development
Tolerance Bio signs $560m worldwide TLB-33 deal with Tanabe Pharma
Mirum and Incyte’s Atebrioz approved for FOP in US
Amberstone and Henlius agree to develop solid-tumour T-cell engagers
FDA approves Lilly’s Onswik for type 2 diabetes in adults
Genialis and Inventia to enhance pancreatic cancer treatment testing
Basecamp Research secures $140m for AI-driven therapies
BoomRay and Novartis sign $900m deal for radioligand therapy
